Administration of insulin like growth factor I (IGF[sbnd]I) lowers serum lipoprotein(a)-impact on atherosclerotic cardiovascular disease

Zvi Laron; Haim Werner

doi:10.1016/j.ghir.2023.101548

Administration of insulin like growth factor I (IGF[sbnd]I) lowers serum lipoprotein(a)-impact on atherosclerotic cardiovascular disease

Zvi Laron^*, Haim Werner

^*Corresponding author for this work

Human Molecular Genetics Biochemistry

Schneider Childrens Medical Center Israel

Research output: Contribution to journal › Review article › peer-review

Abstract

Insulin like growth factor I (IGF[sbnd]I) secreted by the liver upon stimulation by pituitary growth hormone (GH) acts as the most important growth stimulating hormone in children. The present review presents evidence that among its additional metabolic effects, IGF-I suppresses the synthesis of lipoprotein(a) [Lp(a)], an independent risk factor for atherosclerotic cardiovascular disease. In view of this property, it is suggested that the addition of IGF-I to the armamentarium of hyperlipoproteinemia treatment should be considered.

Original language	English
Article number	101548
Journal	Growth Hormone and IGF Research
Volume	71
DOIs	https://doi.org/10.1016/j.ghir.2023.101548
State	Published - Aug 2023

Keywords

Atherosclerotic cardiovascular disease
IGF-I
IGF-treatment
Lipoprotein(a)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ghir.2023.101548

Cite this

@article{9f8e8b13d1b2480f9af8d9bdcbc77f9d,

title = "Administration of insulin like growth factor I (IGF[sbnd]I) lowers serum lipoprotein(a)-impact on atherosclerotic cardiovascular disease",

abstract = "Insulin like growth factor I (IGF[sbnd]I) secreted by the liver upon stimulation by pituitary growth hormone (GH) acts as the most important growth stimulating hormone in children. The present review presents evidence that among its additional metabolic effects, IGF-I suppresses the synthesis of lipoprotein(a) [Lp(a)], an independent risk factor for atherosclerotic cardiovascular disease. In view of this property, it is suggested that the addition of IGF-I to the armamentarium of hyperlipoproteinemia treatment should be considered.",

keywords = "Atherosclerotic cardiovascular disease, IGF-I, IGF-treatment, Lipoprotein(a)",

author = "Zvi Laron and Haim Werner",

note = "Publisher Copyright: {\textcopyright} 2023",

year = "2023",

month = aug,

doi = "10.1016/j.ghir.2023.101548",

language = "אנגלית",

volume = "71",

journal = "Growth Hormone and IGF Research",

issn = "1096-6374",

publisher = "Elsevier Ltd.",

}

TY - JOUR

T1 - Administration of insulin like growth factor I (IGF[sbnd]I) lowers serum lipoprotein(a)-impact on atherosclerotic cardiovascular disease

AU - Laron, Zvi

AU - Werner, Haim

PY - 2023/8

Y1 - 2023/8

N2 - Insulin like growth factor I (IGF[sbnd]I) secreted by the liver upon stimulation by pituitary growth hormone (GH) acts as the most important growth stimulating hormone in children. The present review presents evidence that among its additional metabolic effects, IGF-I suppresses the synthesis of lipoprotein(a) [Lp(a)], an independent risk factor for atherosclerotic cardiovascular disease. In view of this property, it is suggested that the addition of IGF-I to the armamentarium of hyperlipoproteinemia treatment should be considered.

AB - Insulin like growth factor I (IGF[sbnd]I) secreted by the liver upon stimulation by pituitary growth hormone (GH) acts as the most important growth stimulating hormone in children. The present review presents evidence that among its additional metabolic effects, IGF-I suppresses the synthesis of lipoprotein(a) [Lp(a)], an independent risk factor for atherosclerotic cardiovascular disease. In view of this property, it is suggested that the addition of IGF-I to the armamentarium of hyperlipoproteinemia treatment should be considered.

KW - Atherosclerotic cardiovascular disease

KW - IGF-I

KW - IGF-treatment

KW - Lipoprotein(a)

UR - http://www.scopus.com/inward/record.url?scp=85168322996&partnerID=8YFLogxK

U2 - 10.1016/j.ghir.2023.101548

DO - 10.1016/j.ghir.2023.101548

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

C2 - 37598644

AN - SCOPUS:85168322996

SN - 1096-6374

VL - 71

JO - Growth Hormone and IGF Research

JF - Growth Hormone and IGF Research

M1 - 101548

ER -

Administration of insulin like growth factor I (IGF[sbnd]I) lowers serum lipoprotein(a)-impact on atherosclerotic cardiovascular disease

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this